PPARG and metabolic dysfunction-associated steatohepatitis: Even though activation of PPARγ is steatogenic, treatment with PPARγ ligands to genetically obese or diet-induced NASH mice decreases hepatic TAG due to adiponectic-mediated glucose uptake and AMPK activation, thereby improving FA oxidation in hepatocytes [62].